- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sanjivani Parenteral's Q1 FY26 earnings call highlighted revenue growth of 8.9% to ₹17.9 Cr, with EBITDA up 10.8% to ₹2.7 Cr, achieving a 15% margin. Profit after tax was flat at ₹1.7 Cr due to higher depreciation and interest expenses. Management noted that global supply chain issues and geopolitical tensions impacted shipments, but underlying demand remains strong, and logistics are easing. The Pune IV products plant is set to receive its commercial license and commence production by early September, projected to contribute ₹75-80 Cr annually. The Prague nutraceutical joint venture has begun processing small orders, with income anticipated in Q4. The company continues to expand its product offerings.